{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:33:08Z","timestamp":1792517588900,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009256.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000}}],"reference-count":51,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009256.pub3","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T12:00:46Z","timestamp":1578916846000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer"],"prefix":"10.1002","volume":"2020","author":[{"given":"Vitor F","family":"Vasconcellos","sequence":"first","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP\/FMUSP); Medical Oncology; Av. Dr Arnaldo 251 S\u00e3o Paulo Sao Paulo Brazil 01246-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme N","family":"Marta","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP\/FMUSP); Medical Oncology; Av. Dr Arnaldo 251 S\u00e3o Paulo Sao Paulo Brazil 01246-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina MK","family":"da Silva","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Emergency Medicine and Evidence Based Medicine; Rua Borges Lagoa 564 cj 64 Vl. Clementino S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aecio FT","family":"Gois","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Pedro de Toledo, 598 S\u00e3o Paulo S\u00e3o Paulo Brazil 04039-001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago B","family":"de Castria","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP\/FMUSP); Medical Oncology; Av. Dr Arnaldo 251 S\u00e3o Paulo Sao Paulo Brazil 01246-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Riera","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Pedro de Toledo, 598 S\u00e3o Paulo S\u00e3o Paulo Brazil 04039-001"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD009256.pub3-BIB0001|cit1","first-page":"427","article-title":"Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer","volume":"5","author":"Cai","year":"2002","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"2","key":"10.1002\/14651858.CD009256.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1556-0864(15)31529-X","article-title":"A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly","volume":"1","author":"Chen","year":"2006","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"302-12","DOI":"10.1016\/j.ejca.2017.05.037","article-title":"Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial","volume":"83","author":"Ferry","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"16","key":"10.1002\/14651858.CD009256.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009256.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-5002(03)00140-5","article-title":"Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer","volume":"41","author":"Mazzanti","year":"2003","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1002\/14651858.CD009256.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdf332","article-title":"Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial","volume":"13","author":"Rosell","year":"2002","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009256.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/0973-1482.187287","article-title":"A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer","volume":"13","author":"Saad","year":"2017","journal-title":"Journal of Cancer Research and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD009256.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009256.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD009256.pub3-BIB0010|cit10","first-page":"188","article-title":"A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non-small cell lung cancer","volume":"4","author":"Yan","year":"2001","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"3","key":"10.1002\/14651858.CD009256.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0169-5002(03)00233-2","article-title":"Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial","volume":"41","author":"Zatloukal","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"A41","DOI":"10.1136\/thoraxjnl-2011-201054b.86","article-title":"Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients","volume":"66","author":"Billingham","year":"2011","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD009256.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2015.05.016","article-title":"Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: comparison of two chemotherapy regimens (IFCT-0702: a randomized phase 3 final results study)","volume":"89","author":"Moro-Sibilot","year":"2015","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1002\/14651858.CD009256.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cllc.2012.10.001","article-title":"A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer","volume":"14","author":"Schuette","year":"2013","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2015.11.022","article-title":"Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: analysis from the European FRAME study","volume":"92","author":"Smit","year":"2016","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1002\/14651858.CD009256.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1097\/JTO.0000000000000246","article-title":"Cisplatin or carboplatin for advanced non-small cell lung cancer?","volume":"9","author":"Sun","year":"2014","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD009256.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/JTO.0000000000000272","article-title":"First-line chemotherapy treatment of advanced non-small-cell lung cancer. Does cisplatin versus carboplatin make a difference?","volume":"9","author":"Tiseo","year":"2014","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.lungcan.2017.07.031","article-title":"Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study","volume":"112","author":"Verschuer","year":"2017","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1002\/14651858.CD009256.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"issue":"9","key":"10.1002\/14651858.CD009256.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/JTO.0b013e31814617a2","article-title":"Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis","volume":"2","author":"Baggstrom","year":"2007","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009256.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2015.62.2860","article-title":"Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries","volume":"34","author":"Souza","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009256.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0023|cit23","first-page":"394-424","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0024|cit24","unstructured":"McMaster University (developed by Evidence Prime, Inc.) GRADEpro Guideline Development Tool 2015. Available at gradepro.org"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0025|cit25","volume-title":"Clinical trials in oncology","author":"Green","year":"2003"},{"issue":"May 21;1:15009","key":"10.1002\/14651858.CD009256.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1:16","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nature Reviews Disease Primers"},{"issue":"30","key":"10.1002\/14651858.CD009256.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0028|cit28","unstructured":"Higgins JPT Green S editor(s) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies","volume":"102","author":"Ho","year":"2016","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"19","key":"10.1002\/14651858.CD009256.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2004.02.109","article-title":"Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer","volume":"22","author":"Hotta","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009256.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.lungcan.2007.03.014","article-title":"A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer","volume":"57","author":"Jiang","year":"2007","journal-title":"Lung Cancer"},{"issue":"19","key":"10.1002\/14651858.CD009256.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1002\/14651858.CD009256.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009256.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.18.01534","article-title":"Does platinum-based chemotherapy still have a role in first-line treatment of advanced non-small-cell lung cancer?","volume":"37","author":"Lisberg","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0035|cit35","unstructured":"National Cancer Institute Common toxicity criteria ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Noone AM Cronin KA Altekruse SF Howlader N Lewis DR Petkov VI Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results program, 1992-2013 Cancer Epidemiology, Biomarkers & Prevention 2017 632 41 10.1158\/1055-9965.EPI-16-0520","DOI":"10.1158\/1055-9965.EPI-16-0520"},{"issue":"7010","key":"10.1002\/14651858.CD009256.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","author":"NSCLC Collaborative Group","year":"1995","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0038|cit38","first-page":"199","article-title":"Platinum analogs","volume-title":"Cancer: principles and practice of oncology","author":"O\u2019Dwyer","year":"2015"},{"issue":"1","key":"10.1002\/14651858.CD009256.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-5002(03)00280-0","article-title":"Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial","volume":"43","author":"Paccagnella","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mrrev.2016.11.003","article-title":"Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer","volume":"771","author":"Perez-Ramirez","year":"2017","journal-title":"Mutation Research"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"9","key":"10.1002\/14651858.CD009256.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0044|cit44","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"24","key":"10.1002\/14651858.CD009256.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0047|cit47","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0048|cit48","volume-title":"Union for International Cancer Control (UICC), TNM Classification of Malignant Tumours","volume":"1","author":"Sobin","year":"2002"},{"key":"10.1002\/14651858.CD009256.pub3-BIB0049|cit49","unstructured":"Vasconcellos VF Colli LM Awada A de Castro Junior G Precision oncology: as much expectations as limitations ecancermedicalscience 2018 ed86"},{"issue":"4","key":"10.1002\/14651858.CD009256.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1054\/bjoc.2000.1643","article-title":"Estimation of glomerular filtration rate in cancer patients","volume":"84","author":"Wright","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD009256.pub3-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009256.pub2","article-title":"Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer","author":"Castria","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009256.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T09:18:00Z","timestamp":1668071880000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009256.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009256.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}